文献速递消化道肿瘤放疗放疗物理与技术

新型液体基准标记在食管癌图像引导放疗中的技术可行性与影像可见性

A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging.
PubMed 文献 · Pract Radiat Oncol · 2019-07-04

本研究评估了新型液体基准标记(BioXmark)在食管癌放疗中注射的技术可行性、影像可见性和位置稳定性。离体实验确定最佳注射体积为0.1 mL,在体10例患者共注射28枚标记,无不良反应,注射体积>0.05 mL的标记在CT、CBCT和MRI上均可见,且在CBCT上位置稳定无时间趋势。

要点

  • 食管癌患者内镜(超声)引导下注射液体基准标记技术可行,未发现不良反应。
  • 注射体积>0.05 mL的标记在CT、CBCT和MRI上均可见,且位置稳定。
  • 该液体基准标记有望用于食管癌图像引导放疗。

核心结论

  • 食管癌放疗中注射液体基准标记技术可行,无不良反应,体积>0.05 mL的标记在CT、CBCT和MRI上可见且位置稳定。

研究设计与样本

  • 离体实验:在猪组织中分析不同体积液体标记在CT、CBCT和MRI上的可见性。
  • 在体部分:在内镜(超声)引导下为10例可治愈食管癌患者注射液体基准标记,评估注射可行性和临床性能。
  • 采集计划CT、每日CBCT和系列MRI(3例患者亚组在放化疗前、中、后)。

主要发现

  • 离体实验中,无伪影良好可见的最佳注射体积为每枚标记0.1 mL。
  • 在体共10例患者注射28枚标记(范围0.025-0.1 mL),未发现不良反应。
  • 24枚标记中19枚(79%)在CT上可见,4枚中3枚(75%)在MRI上可见,24枚中19枚(79%)在首次CBCT上可见。
  • 所有注射体积>0.05 mL的标记在不同影像模态上均可见。
  • CBCT位置稳定性分析未发现放疗疗程中的时间趋势,0.05和0.025 mL标记在CT或CBCT上未检测到伪影。

关键数值与推荐

  • 离体实验确定无伪影良好可见的最佳注射体积为每枚标记0.1 mL。
  • 在体注射体积范围0.025-0.1 mL,体积>0.05 mL的标记在CT、CBCT和MRI上均可见。

临床怎么用

  • 食管癌图像引导放疗中可考虑使用液体基准标记,注射体积>0.05 mL以保证多模态影像可见性。
  • 内镜(超声)引导下注射技术可行,未报告不良反应,但需注意学习曲线(前2例为学习病例)。

局限性

  • 在体样本量较小(10例患者),前2例(4枚标记)被视为学习病例。
  • MRI可见性仅在4枚标记中评估(75%可见),亚组MRI系列仅3例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the technical feasibility of injection, visibility on imaging modalities, and positional stability of a novel liquid fiducial marker (ie, BioXmark) for radiation therapy in patients with esophageal cancer. METHODS: First, the visibility on imaging of different volumes of the liquid marker was analyzed ex vivo in porcine tissue (ie, on computed tomography [CT], cone beam CT (CBCT), and magnetic resonance imaging [MRI]). Next, for the in vivo part, the liquid fiducial markers were injected under endoscopic (ultrasound) guidance in 10 patients with curable esophageal cancer. The technical feasibility of the injection procedure and the clinical performance (ie, visibility and positional stability on imaging) were evaluated. Planning CT, daily CBCT, and serial MRI images (before, during, and after chemoradiation therapy in a subset of 3 patients) were acquired. RESULTS: Ex vivo, the optimal volume for good visibility without artifacts was 0.1 mL per injected marker. In vivo, a total of 28 markers were injected in 10 patients (range, 0.025-0.1 mL). No adverse effects were identified. The first 2 cases (4 markers) were considered as learning cases. A total of 19 of 24 of the liquid markers (79%) were visible on CT, 3 of 4 (75%) on MRI, and 19 of 24 (79%) on the first CBCT. All markers with an injected volume of >0.05 mL were visible on the different imaging modalities. Positional stability analysis on CBCT identified no time trend during the radiation therapy course. No artifacts could be detected for liquid marker volumes of 0.05 and 0.025 mL in CT or CBCT. CONCLUSIONS: Injection of a liquid fiducial marker for esophageal cancer radiation therapy is technically feasible with no adverse events identified. Volumes of >0.05 mL have an appropriate visibility on CT, CBCT, and MRI, with an excellent positional stability. Liquid fiducial markers are therefore promising for use in image guided radiation therapy.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Machiels M, Voncken FEM, Jin P, et al. A Novel Liquid Fiducial Marker in Esophageal Cancer Image Guided Radiation Therapy: Technical Feasibility and Visibility on Imaging. Pract Radiat Oncol. 2019. PMID: 31279938. doi:10.1016/j.prro.2019.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。